acetylcarnitine has been researched along with Peripheral Nerve Diseases in 44 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 9.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 7.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
| "This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 7.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 6.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| " Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 5.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 5.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 3.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
| "This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 3.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 2.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)." | 2.78 | A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013) |
| "Methods." | 2.78 | A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013) |
| "Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
| "Peripheral neuropathies are extremely heterogeneous nosological entities." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
| "CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life." | 2.44 | Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. ( Abbott, L; Aschenbrenner, J; Collins, M; Hart, C; Visovsky, C, 2007) |
| " Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 1.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
| "OVCAR-3 and SKOV-3 ovarian cancer lines were incubated in ALCAR containing media." | 1.35 | Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. ( Belisle, JA; Engle, DB; Gubbels, JA; Hutson, PR; Kushner, DM; Patankar, MS; Petrie, SE, 2009) |
| "Peripheral neuropathies are widespread disorders induced by autoimmune diseases, drug or toxin exposure, infections, metabolic insults or trauma." | 1.34 | Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. ( Bartolini, A; Calvani, M; Di Cesare Mannelli, L; Ghelardini, C; Mosconi, L; Nicolai, R; Pacini, A; Vivoli, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (20.45) | 18.2507 |
| 2000's | 19 (43.18) | 29.6817 |
| 2010's | 15 (34.09) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Parisi, S | 1 |
| Ditto, MC | 1 |
| Borrelli, R | 1 |
| Fusaro, E | 1 |
| Dinicola, S | 1 |
| Fuso, A | 1 |
| Cucina, A | 1 |
| Santiago-Reyes, M | 1 |
| Verna, R | 1 |
| Unfer, V | 1 |
| Monastra, G | 1 |
| Bizzarri, M | 1 |
| Rowin, J | 1 |
| Schloss, JM | 1 |
| Colosimo, M | 1 |
| Airey, C | 1 |
| Masci, PP | 1 |
| Linnane, AW | 1 |
| Vitetta, L | 1 |
| Hershman, DL | 1 |
| Unger, JM | 1 |
| Crew, KD | 1 |
| Minasian, LM | 1 |
| Awad, D | 1 |
| Moinpour, CM | 1 |
| Hansen, L | 1 |
| Lew, DL | 1 |
| Greenlee, H | 1 |
| Fehrenbacher, L | 1 |
| Wade, JL | 1 |
| Wong, SF | 1 |
| Hortobagyi, GN | 1 |
| Meyskens, FL | 1 |
| Albain, KS | 1 |
| Hutchinson, L | 1 |
| Onofrj, M | 2 |
| Ciccocioppo, F | 1 |
| Varanese, S | 1 |
| di Muzio, A | 1 |
| Calvani, M | 3 |
| Chiechio, S | 3 |
| Osio, M | 3 |
| Thomas, A | 1 |
| Campone, M | 1 |
| Berton-Rigaud, D | 1 |
| Joly-Lobbedez, F | 1 |
| Baurain, JF | 1 |
| Rolland, F | 1 |
| Stenzl, A | 1 |
| Fabbro, M | 1 |
| van Dijk, M | 1 |
| Pinkert, J | 1 |
| Schmelter, T | 1 |
| de Bont, N | 1 |
| Pautier, P | 1 |
| Burotto, M | 1 |
| Fojo, AT | 1 |
| Callander, N | 1 |
| Markovina, S | 1 |
| Eickhoff, J | 1 |
| Hutson, P | 1 |
| Campbell, T | 1 |
| Hematti, P | 1 |
| Go, R | 1 |
| Hegeman, R | 1 |
| Longo, W | 1 |
| Williams, E | 1 |
| Asimakopoulos, F | 1 |
| Miyamoto, S | 1 |
| Onysko, M | 1 |
| Legerski, P | 1 |
| Potthoff, J | 1 |
| Erlandson, M | 1 |
| Traina, G | 1 |
| van Dam, DG | 1 |
| Beijers, AJ | 1 |
| Vreugdenhil, G | 1 |
| Wolf, S | 1 |
| Barton, D | 1 |
| Kottschade, L | 1 |
| Grothey, A | 1 |
| Loprinzi, C | 1 |
| Valcour, V | 1 |
| Yeh, TM | 1 |
| Bartt, R | 1 |
| Clifford, D | 1 |
| Gerschenson, M | 1 |
| Evans, SR | 1 |
| Cohen, BA | 1 |
| Ebenezer, GJ | 1 |
| Hauer, P | 1 |
| Millar, L | 1 |
| Gould, M | 1 |
| Tran, P | 1 |
| Shikuma, C | 1 |
| Souza, S | 1 |
| McArthur, JC | 1 |
| Engle, DB | 1 |
| Belisle, JA | 1 |
| Gubbels, JA | 1 |
| Petrie, SE | 1 |
| Hutson, PR | 1 |
| Kushner, DM | 1 |
| Patankar, MS | 1 |
| Vivoli, E | 2 |
| Di Cesare Mannelli, L | 2 |
| Salvicchi, A | 1 |
| Bartolini, A | 2 |
| Koverech, A | 1 |
| Nicolai, R | 3 |
| Benatti, P | 1 |
| Ghelardini, C | 2 |
| Binienda, ZK | 1 |
| Beaudoin, MA | 1 |
| Gough, B | 1 |
| Ali, SF | 1 |
| Virmani, A | 1 |
| Zheng, H | 1 |
| Xiao, WH | 4 |
| Bennett, GJ | 4 |
| Hart, AM | 1 |
| Wilson, AD | 1 |
| Montovani, C | 1 |
| Smith, C | 1 |
| Johnson, M | 1 |
| Terenghi, G | 1 |
| Youle, M | 2 |
| Copani, A | 2 |
| Melchiorri, D | 1 |
| Canudas, AM | 1 |
| Storto, M | 1 |
| Nicoletti, F | 2 |
| Flatters, SJ | 2 |
| Muscia, F | 1 |
| Zampini, L | 1 |
| Nascimbene, C | 2 |
| Mailland, E | 2 |
| Cargnel, A | 1 |
| Mariani, C | 2 |
| Vanotti, A | 1 |
| Capiluppi, E | 1 |
| Gereau, RW | 1 |
| De Grandis, D | 1 |
| Mosconi, L | 1 |
| Pacini, A | 1 |
| Visovsky, C | 1 |
| Collins, M | 1 |
| Abbott, L | 1 |
| Aschenbrenner, J | 1 |
| Hart, C | 1 |
| Jin, HW | 1 |
| Mulhern, HL | 1 |
| Fulgente, T | 1 |
| Melchionda, D | 1 |
| Marchionni, A | 1 |
| Tomasello, F | 1 |
| Salpietro, FM | 1 |
| Alafaci, C | 1 |
| De Sanctis, E | 1 |
| Pennisi, G | 1 |
| Bella, R | 1 |
| Famularo, G | 2 |
| Moretti, S | 1 |
| Marcellini, S | 1 |
| Trinchieri, V | 1 |
| Tzantzoglou, S | 1 |
| Santini, G | 1 |
| Longo, A | 1 |
| De Simone, C | 2 |
| Scarpini, E | 1 |
| Sacilotto, G | 1 |
| Baron, P | 1 |
| Cusini, M | 1 |
| Scarlato, G | 1 |
| James, JS | 1 |
| Tenconi, B | 1 |
| Donadoni, L | 1 |
| Germani, E | 1 |
| Bertelli, A | 1 |
| Mantegazza, P | 1 |
| Di Giulio, AM | 1 |
| Ramacci, MT | 2 |
| Gorio, A | 1 |
| De Angelis, C | 1 |
| Scarfò, C | 1 |
| Falcinelli, M | 1 |
| Reda, E | 1 |
| Angelucci, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy： A Randomized, Controlled, Open-label, Phase 2 Trail[NCT05601479] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-11-01 | Not yet recruiting | ||
| S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III[NCT00775645] | Phase 3 | 437 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone[NCT00468481] | Phase 3 | 385 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| (REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.[NCT00751205] | Phase 2 | 150 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer : A Prospective Observational Study[NCT03022162] | 150 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy[NCT00863057] | Phase 2 | 15 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Due to slow rate of enrollment, which compromised the ability to meet study objectives in a timely manner.) | ||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy[NCT00050271] | 27 participants (Actual) | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare fatigue outcome between treatment and placebo groups as measured by the 13-item Functional Assessment of Chronic Illness Therapy FACIT-fatigue questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate more fatigue. Total possible range is 0 to 52. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | FACIT-fatigue score (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 36.6 |
| Arm II (Placebo) | 35.3 |
Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 35.4 |
| Arm II (Placebo) | 36.3 |
Compare FACT-TOI outcome in treatment vs placebo groups at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse functional status. Total possible range is 0 to 120. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 92.1 |
| Arm II (Placebo) | 92.3 |
Proportion of patients experiencing grade 3 or 4 neuropathy (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 8 |
| Arm II (Placebo) | 1 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 17.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.3 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 17.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 2.4 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 15.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -1.6 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 15.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.6 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 18.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 2.2 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.1 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.2 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 24
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0.1 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 0 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | µg/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 0 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 405.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 86.5 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 448.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 68.0 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 452.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 64.6 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 110.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -37.6 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 310.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 68.2 |
The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24
| Intervention | per 1000 birth (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | -0.51 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | -0.03 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 50.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 47.1 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 67.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 46.4 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 67.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 51.8 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 61.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 45.9 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 64.0 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.7 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 45.9 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 68.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 54.1 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 41.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.5 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 42.3 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.4 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.2 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 39.7 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 58.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 39.8 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 59.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 43.1 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.8 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1122.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1345.0 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1469.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1378.4 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1460.5 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1454.7 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1486.6 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1435.9 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1500.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1316.1 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1175.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1256.1 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1412.7 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1407.6 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 910.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 915.1 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1308.9 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1025.2 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1365.2 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 967.6 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1419.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 981.3 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1355.3 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 949.2 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1007.1 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 889.5 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8
| Intervention | nmol/L (Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1184.8 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 970.4 |
Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 60.55 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 41.67 |
RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) | 1406.91 |
| Drospirenone (DRSP)/Ethinylestradiol (EE) | 1022.21 |
The CES-D is a 20-item self-report rating inventory measuring characteristic attitudes and symptoms of depression. Participants were asked to score each item: (0) Rarely, (1) Occasionally, (2) Sometimes, and (3) Most of time. Some items are multiplied by -1 to change direction. The overall CES-D score is simply the sum of 20 items. The highest possible total CES-D score is 48, and the lowest possible score is -12. The total CES-D score is considered missing if more than 4 items are not answered. (NCT00863057)
Timeframe: At the fourth treatment week of each treatment period
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine and Methadone | 13.8 |
| Duloxetine and Methadone Placebo | 13.8 |
| Duloxetine Placebo and Methadone | 13.3 |
| Duloxetine Placebo and Methadone Placebo | 13.3 |
(NCT00863057)
Timeframe: During each treatment period
| Intervention | mg (Number) |
|---|---|
| Methadone | 30 |
| Duloxetine | 60 |
"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine.~Participants were given pain diaries at weeks 0, 5, 10, and 15. They started the diary 7 days prior to their clinic visits at weeks 0, 4, 9, 14, and 19. During the 7 days, each morning, they recorded their pain level due to neuropathy by circling the number that best described their neuropathy pain on average during the night time." (NCT00863057)
Timeframe: Over the fourth treatment week of each treatment period
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine and Methadone | 5.20 |
| Duloxetine and Methadone Placebo | 5.82 |
| Duloxetine Placebo and Methadone | 5.90 |
| Duloxetine Placebo and Methadone Placebo | 6.10 |
"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine at baseline and over the fourth treatment week of each treatment period.~The % of improvement was calculated as (x-y)/x,where x was the MPI score at baseline, and y was the MPI score at the end of each treatment stage." (NCT00863057)
Timeframe: At Baseline and over the fourth treatment week of each treatment period
| Intervention | participants (Number) |
|---|---|
| Duloxetine and Methadone | 2 |
| Duloxetine and Methadone Placebo | 2 |
| Duloxetine Placebo and Methadone | 2 |
| Duloxetine Placebo and Methadone Placebo | 2 |
"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine at baseline and over the fourth treatment week of each treatment period.~The % of improvement was calculated as (x-y)/x,where x was the MPI score at baseline, and y was the MPI score at the end of each treatment stage." (NCT00863057)
Timeframe: At Baseline and over the fourth treatment week of each treatment period
| Intervention | participants (Number) |
|---|---|
| Duloxetine and Methadone | 2 |
| Duloxetine and Methadone Placebo | 2 |
| Duloxetine Placebo and Methadone | 1 |
| Duloxetine Placebo and Methadone Placebo | 2 |
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 was used (see the link to the grading table in Protocol Section) (NCT00863057)
Timeframe: From study entry to end of study at week 20 or premature study discontinuation
| Intervention | Participants (Count of Participants) |
|---|---|
| Duloxetine and Methadone | 5 |
| Duloxetine and Methadone Placebo | 4 |
| Duloxetine Placebo and Methadone | 6 |
| Duloxetine Placebo and Methadone Placebo | 5 |
"The BPI interference scale measured level of interference with the following seven items:~General activity~Mood~Walking ability~Normal work~Relations with other people~Sleep~Enjoyment of life~Interference scales range from 0='Does not interfere' to 10='Completely interferes'. The overall BPI score is the mean of seven item with the minimum and maximal scores of 0 and 70, respectively." (NCT00863057)
Timeframe: At the fourth week of each treatment period
| Intervention | Scores on a scale (Median) |
|---|---|
| Duloxetine and Methadone | 3.14 |
| Duloxetine and Methadone Placebo | 4.14 |
| Duloxetine Placebo and Methadone | 3.64 |
| Duloxetine Placebo and Methadone Placebo | 3.14 |
"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine.~Participants were given pain diaries at weeks 0, 5, 10, and 15. They started the diary 7 days prior to their clinic visits at weeks 0, 4, 9, 14, and 19. During the 7 days, each morning, they recorded their pain level due to neuropathy by circling the number that best described their neuropathy pain on average over the past 24 hours." (NCT00863057)
Timeframe: During the fourth treatment week of each treatment period
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine and Methadone | 5.20 |
| Duloxetine and Methadone Placebo | 5.91 |
| Duloxetine Placebo and Methadone | 6.20 |
| Duloxetine Placebo and Methadone Placebo | 5.70 |
"The GIC scale is a validated instrument that consists of seven verbal descriptors on a 7-point scale:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Much worse~Very much worse~Participants were carefully instructed to consider the impact of study treatments on their level of neuropathic pain intensity during the baseline phase of the study." (NCT00863057)
Timeframe: At the fourth treatment week of each treatment period
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PGIC - Very much improved | PGIC - Much improved | PGIC - Minimally improved | PGIC - No change | PGIC - Much worse | CGIC - Very much improved | CGIC - Much improved | CGIC - Minimally improved | CGIC - No change | CGIC - Much worse | |
| Duloxetine and Methadone | 1 | 4 | 2 | 3 | 0 | 1 | 4 | 1 | 4 | 0 |
| Duloxetine and Methadone Placebo | 0 | 1 | 4 | 6 | 0 | 1 | 1 | 1 | 8 | 0 |
| Duloxetine Placebo and Methadone | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 3 | 3 | 0 |
| Duloxetine Placebo and Methadone Placebo | 1 | 1 | 4 | 4 | 0 | 1 | 1 | 3 | 4 | 1 |
(NCT00863057)
Timeframe: During each treatment period and the subsequent cross-over (or final study week) period
| Intervention | participants (Number) | |
|---|---|---|
| Treatment period (1-4, 6-9, 11-14, 16-19 weeks) | Cross-over period (5, 10, 15, 20 weeks) | |
| Duloxetine and Methadone | 0 | 1 |
| Duloxetine and Methadone Placebo | 0 | 0 |
| Duloxetine Placebo and Methadone | 0 | 1 |
| Duloxetine Placebo and Methadone Placebo | 2 | 1 |
13 reviews available for acetylcarnitine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy.
Topics: Acetylcarnitine; Animals; Antineoplastic Agents; Biological Products; Humans; Peripheral Nervous Sys | 2018 |
Integrative neuromuscular medicine: Neuropathy and neuropathic pain: Consider the alternatives.
Topics: Acetylcarnitine; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Diet; Diet Therapy; Dietary Supp | 2019 |
Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review.
Topics: Acetylcarnitine; Acetylcysteine; Antineoplastic Agents; Dietary Supplements; Fatty Acids, Omega-3; G | 2013 |
Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond.
Topics: Acetylcarnitine; Animals; Humans; Neuralgia; Nootropic Agents; Peripheral Nervous System Diseases | 2013 |
Targeting neuropathic pain: consider these alternatives.
Topics: Acetylcarnitine; Capsaicin; Complementary Therapies; Family Practice; gamma-Linolenic Acid; Humans; | 2015 |
The neurobiology of acetyl-L-carnitine.
Topics: Acetylcarnitine; Aging; Animals; Apoptosis; Brain; Dietary Supplements; Energy Metabolism; Epigenesi | 2016 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A | 2008 |
Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain.
Topics: Acetylcarnitine; Analgesics; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Dise | 2004 |
Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.
Topics: Acetylcarnitine; Analgesics, Opioid; Animals; Anticonvulsants; Antidepressive Agents; Antineoplastic | 2007 |
Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.
Topics: Acetylcarnitine; Animals; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; HIV Infec | 2007 |
Acetyl-L-carnitine in neuropathic pain: experimental data.
Topics: Acetylcarnitine; Analgesia; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Disea | 2007 |
Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
Topics: Acetylcarnitine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Nootropic Agents; | 2007 |
Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.
Topics: Acetylcarnitine; Acupuncture Therapy; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplas | 2007 |
9 trials available for acetylcarnitine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind | 2013 |
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug | 2014 |
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy.
Topics: Acetylcarnitine; Adult; Cohort Studies; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu | 2004 |
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study.
Topics: Acetylcarnitine; Adult; Aged; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Middle | 2006 |
Complications & side effects. Supplements and CD4+ counts: study finds surprising results.
Topics: Acetylcarnitine; Acetylcysteine; Antioxidants; CD4 Lymphocyte Count; Dose-Response Relationship, Dru | 2004 |
L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Double-Blind Method; Humans; Injections, Intramuscular; Mi | 1995 |
Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues.
Topics: Acetylcarnitine; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Axons; Cross-Sectional | 1997 |
Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients.
Topics: Acetylcarnitine; Adult; Female; HIV Seropositivity; Humans; Male; Middle Aged; Nootropic Agents; Pai | 1997 |
22 other studies available for acetylcarnitine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases.
Topics: Acetylcarnitine; Aged; Amides; Analgesics, Non-Narcotic; Carpal Tunnel Syndrome; Drug Administration | 2021 |
Chemotherapy: Supplements--for better or worse?
Topics: Acetylcarnitine; Breast Neoplasms; Female; Humans; Peripheral Nervous System Diseases; Taxoids | 2013 |
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?
Topics: Acetylcarnitine; Benzothiazoles; Epothilones; Female; Humans; Male; Peripheral Nervous System Diseas | 2013 |
Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy?
Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Peripheral Nervo | 2016 |
Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection.
Topics: Acetylcarnitine; AIDS-Related Opportunistic Infections; Confidence Intervals; DNA, Mitochondrial; Fe | 2009 |
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cell G | 2009 |
Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy.
Topics: Acetylcarnitine; Analgesics; Animals; Constriction, Pathologic; Ganglia, Spinal; Male; Nerve Growth | 2010 |
Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-l-carnitine and resveratrol.
Topics: Acetylcarnitine; Animals; Antioxidants; Axons; Environmental Pollutants; Male; Nerve Degeneration; N | 2010 |
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; An | 2012 |
Side effects. Helping to repair damaged nerves.
Topics: Acetylcarnitine; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors | 2000 |
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
Topics: Acetylcarnitine; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Male; Paclitaxel; | 2006 |
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E | 2008 |
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E | 2008 |
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E | 2008 |
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E | 2008 |
Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy.
Topics: Acetylcarnitine; Animals; Apoptosis; Blotting, Western; Caspase 3; Cytochromes c; Cytosol; DNA Fragm | 2007 |
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.
Topics: Acetylcarnitine; Animals; Axons; Behavior, Animal; Disease Models, Animal; Drug Interactions; Langer | 2008 |
Treatment with acetyl-L-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positives patients.
Topics: Acetylcarnitine; HIV Seropositivity; Humans; Peripheral Nervous System Diseases | 1998 |
Amino acid may help neuropathy.
Topics: Acetylcarnitine; Anti-HIV Agents; Biopsy; HIV Infections; Humans; Peripheral Nervous System Diseases | 2000 |
Drug-related neuropathy: low acetylcarnitine levels found.
Topics: Acetylcarnitine; Anti-HIV Agents; Humans; Nootropic Agents; Peripheral Nervous System Diseases | 1997 |
What's L-A-C got to do with it?
Topics: Acetylcarnitine; HIV Infections; Humans; Nootropic Agents; Peripheral Nervous System Diseases | 1997 |
Acetylcarnitine and neuropathy: call for information.
Topics: Acetylcarnitine; Clinical Trials as Topic; HIV Infections; Humans; Peripheral Nervous System Disease | 1998 |
. . . from the 3rd International Workshop on salvage therapy for HIV infection.
Topics: Acetylcarnitine; HIV Infections; HIV Protease Inhibitors; Humans; Patient Compliance; Peripheral Ner | 2000 |
Intraspinal degenerative atrophy caused by sciatic nerve lesions prevented by acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Atrophy; Enkephalin, Methionine; Hydroxyindoleacetic Acid; Male; Periphera | 1992 |
Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury.
Topics: Acetylcarnitine; Animals; Male; Nerve Crush; Nerve Degeneration; Nerve Regeneration; Neuromuscular J | 1992 |